Plerixafor use in patients with previous mobilization failure: A multicenter experience

Transfusion and Apheresis Science

Volumn 47, Issue 1, 2012, Pages 77-80

  Tekgündüz, Emre ^a   Altuntaş, Fevzi ^a   Şivgin, Serdar ^b   Aki, Şahika Zeynep ^c   Dönmez, Ayhan ^d   Topçuoĝlu, Pervin ^e   Yildirim, Rahşan ^b   Baysal, Nuran Ahu ^c   Ayyildiz, Erol ^e   Yüksel, Meltem Kurt ^a   Sari, Ismail ^f   Tombuloĝlu, Murat ^d   Ünal, Ali ^b   Ilhan, Osman ^e  

^a ANKARA ONCOLOGY EDUCATION AND RESEARCH HOSPITAL   (Turkey)

^b ERCIYES UNIVERSITY   (Turkey)

^c GAZI UNIVERSITY   (Turkey)

^d EGE UNIVERSITY   (Turkey)

^e ANKARA UNIVERSITY   (Turkey)

^f PAMUKKALE UNIVERSITY   (Turkey)

Author keywords

Chemotherapy; Mobilization failure; Plerixafor; Stem cell mobilization

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; PLERIXAFOR;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CD34+ STEM CELL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; DRUG INDUCED HEADACHE; FEMALE; HUMAN; LYMPHOMA; MALE; MULTICENTER STUDY; MYALGIA; MYELOMA; NAUSEA; STEM CELL; STEM CELL MOBILIZATION;

ADULT; AGED; ANTI-HIV AGENTS; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HETEROCYCLIC COMPOUNDS; HUMANS; LEUKOCYTE COUNT; LYMPHOMA; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS;

EID: 84862859727     PISSN: 14730502     EISSN: 18781683     Source Type: Journal    
DOI: 10.1016/j.transci.2012.05.004     Document Type: Article

References (16)

1. Baldomero H., Grathwohl M., Gratwohl A., Tichelli A., Niederwieser D., Madrigal A., et al. European Group for Blood and Marrow Transplantation EBMT. The EBMT activity survey 2009: trends over the past 5years. Bone Marrow Transplant 2011, 46(4):485-501.
2. Abhyankar S., DeJarnette S., Aljitawi O., Ganguly S., Merkel D., McGuirk J. A risk-based approach to optimize autologous hematopoietic stem cell (HSC) collection with the use of plerixafor. Bone Marrow Transplant 2011, [Epub ahead of print]. 10.1038/bmt.2011.133.
3. Worel N. Plerixafor - the magic bullet in stem cell mobilization failure?. Leuk Res 2011, 35:701-702.
4. Brave M., Farrell A., Lin S.C., Ocheltree T., Miksinski S.P., Lee S.L., et al. FDA review summary: Mozobil in combination with granulocyte colony-stimulating factor to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation. Oncology 2010, 78:282-288.
5. Jantunen E., Kvalheim G. Mobilization strategies in hard-to-mobilize patients with lymphoid malignancies. Eur J Haematol 2010, 85(6):463-471.
6. DiPersio J.F., Micallef I.N., Stiff P.J., Bolwell B.J., Maziarz R.T., Jacobsen E., et al. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with plasebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with Non-Hodgkin's Lymphoma. J Clin Oncol 2009, 27:4767-4773.
7. DiPersio J.F., Stadtmauer E.A., Nademanee A., Micallef I.N., Stiff P.J., Kaufman J.L., et al. Plerixafor and G-CSF versus plasebo plus G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 2009, 113:5720-5726.
8. Calandra G., McCarty J., McGuirk J., et al. AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data. Bone Marrow Transplant 2008, 41:331-338.
9. Duarte R.F., Shaw B.E., Marín P., Kottaridis P., Ortiz M., Morante C., et al. Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use data. Bone Marrow Transplant 2011, 46:52-58.
10. Hübel K., Fresen M.M., Salwender H., Basara N., Beier R., Theurich S., et al. Plerixafor with and without chemotherapy in poor mobilizers: results from the German compassionate use program. Bone Marrow Transplant 2011, 46:1045-1052.
11. Worel N., Rosskopf K., Neumeister P., Kasparu H., Nachbaur D., Russ G., et al. Plerixafor and granulocyte-colony-stimulating factor (G-CSF) in patients with lymphoma and multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy for autologous hematopoietic stem cell mobilization: the Austrian experience on a named patient program. Transfusion 2011, 51:968-975.
12. Basak G.W., Knopinska-Posluszny W., Matuszak M., Kisiel E., Harwrylecka D., Szmigielska-Kaplon A., et al. Hematopoietic stem cell mobilization with the reversible CXCR4 receptor inhibitor plerixafor (AMD3100)-Polish compassionate use experience. Ann Hematol 2011, 90(5):557-568.
13. Gertz M.A. Current status of stem cell mobilization. Br J Haematol 2010, 150:647-662.
14. Jantunen E., Kuittinen T., Mahlamäki E., Pyörälä M., Mäntymaa P., Nousiainen T. Efficacy of pre-emptively used plerixafor in patients mobilizing poorly after chemomobilization: a single centre experience. Eur J Haematol 2011, 86:299-304.
15. Vishnu P., Roy V., Paulsen A., Zubair A.C. Efficacy and cost-benefit analysis of risk-adaptive use of plerixafor for autologous hematopoietic progenitor cell mobilization. Transfusion 2011, [Epub ahead of print]. 10.1111/j.1537-2995.2011.03206.x.
16. Costa L.J., Miller A.N., Alexander E.T., Hogan K.R., Shabbir M., Schaub C., et al. Growth factor and patient-adapted use of plerixafor is superior to CY and growth factor for autologous hematopoietic stem cells mobilization. Bone Marrow Transplant 2011, 46(4):523-528.